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Importance of the field: Major adverse cardiovascular events including stent
thrombosis associated with residual platelet reactivity on antiplatelet treat-
ment in high risk vascular patients is a hot issue that needs a strong effort to be
solved. Dual antiplatelet therapy with clopidogrel and aspirin prevents ische-
mic events and improves outcomes following acute coronary syndromes and
percutaneous coronary intervention. However, adverse cardiovascular events
occur in these patients, and several studies have shown that patients who
suffer cardiovascular complications have high post-treatment platelet reac-
tivity despite antiplatelet treatment. Clopidogrel requires conversion to active
metabolite by CYP isoenzymes. Recently, CYP2C19*2 polymorphism (G681A
nucleotide substitution) has been shown to be associated with decreased
metabolisation of clopidogrel, poor antiaggregant effect and increased
adverse cardiovascular events.
Areas covered in this review: This review summarises the principal studies
contributing to establish the relationship between CYP2C19*2 polymorphism
and adverse outcomes in high risk patients on clopidogrel treatment.
Take home message: Prospective studies are urgently needed to determine
the clinical impact of a score that takes into account individual characteristics
of patients – CYP2C19*2 genotypes, residual platelet reactivity, drug–drug
interaction, as well as traditional and procedural risk factors – for the iden-
tification of the therapeutic strategy that provides the best benefit for the
single subject.
Keywords: acute coronary syndromes, antiaggregant therapy, aspirin,
clopidogrel, CYP2C19 loss-of-function polymorphism, drug eluting stent,
major adverse cardiovascular events, percutaneous coronary interventions, stent thrombosis
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1. Introduction
Dual antiplatelet treatment with clopidogrel and acetyl salicylic acid (aspirin) is the
standard treatment for the prevention of stent thrombosis (ST) [1-3]. Retrospective
studies have shown that the discontinuation of clopidogrel, even after ‡ 6 months
after stent implantation, is associated with an increased risk of thrombotic events in
patients with drug-eluting stents (DESs) [4-7]. However, ST can also occur in patients
taking clopidogrel and aspirin, and several retrospective and prospective studies [8-18]
have shown that patients who suffer ST have a high post-treatment platelet reactivity
despite the dual antiplatelet treatment, suggesting that platelet aggregation
nonresponsiveness to clopidogrel is the main cause of the thrombotic event.
Multiple potential or well-documented mechanisms have been identified (Figure 1).
Extrinsic or chronic mechanisms include inadequate drug compliance [19], drug–drug
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interactions [20-23], age, diabetes mellitus, elevated body mass
index and left ventricle ejection function [14,19]. Transient
mechanisms include inflammation [24], accelerated platelet
turnover [25], reticulated platelets (RPs) [25,26], erythrocyte
deformability [27,28] and ADAMTS-13 activity [29].
Among the possible mechanisms, common genetic variants
could play a pivotal role in determining the individual
susceptibility to antiplatelet drug response. Several poly-
morphisms in genes coding platelet components [glyco-
protein (Gp)Ia, GpIIIa, GpIbalpha, GpVI, ADP receptor
P2Y12 (P2Y12), P-selectin, COX-1, COX-2,], eNOS or
CYP enzyme isoforms (-3A4, -3A5) have been proposed
and investigated [30-33]. As regards responsiveness to clopido-
grel, studies in healthy subjects on clopidogrel treatment [34,35]
and in acute coronary syndrome (ACS) patients under-
going percutaneous coronary interventions (PCIs) on dual
antiplatelet treatment [36,37] showed that the CYP2C19*2
allelic variant is an independent predictor of antiplatelet
treatment variability.
Recently, different groups have contemporarily demon-
strated in different clinical settings and at different follow-
up times that CYP2C19*2 is a determinant of the occurrence
of major adverse cardiovascular events (MACEs) in patients
on clopidogrel therapy [38-42] with an estimated risk factor
ranging from 1.5 to 6.0.
In this article, we review the evidences on the relation of
CYP2C19 loss-of-function polymorphism to the occurrence
of coronary ST.
2. Clopidogrel metabolism
Diverse agonists are known to activate platelet aggregation
and fibrinogen binding to the subsequently activated integrin
GPIIb–IIIa complex. In this process, ADP is of particular
importance because it is released by damaged cells and
activated platelets, thus enhancing the action of many
platelet activators [43]. ADP mediates platelet aggregation
through its binding to two G protein-coupled receptors,
P2Y1 and P2Y12, acting together to achieve complete aggre-
gation [44]. P2Y12 also has an important role in amplifying
the responses to other agonists. In fact, ADP is released from
platelet dense granules regardless of the activating stimulus,
be it thrombin, collagen, thromboxane A2 or other agonists.
Therefore, P2Y12 has a major role in arterial thrombosis and
the concomitant inflammatory response and pharmacological
targeting of this receptor has become an important
strategy in cardiovascular disease. Clopidogrel, a P2Y12
ADP-receptor antagonist, is a prodrug converted to its active
thiol metabolite (SR26334) in two sequential oxidation
steps, both occurring in the liver, by the hepatic CYP450
(Figure 2) [45,46]. Clopidogrel is absorbed in the duodenum:
the P-glycoprotein coded by the ABCB1 gene is involved in
the intestinal transport. Only ~ 15% of clopidogrel under-
goes metabolism by CYP450. It is mostly hydrolysed by
esterases to an inactive carboxylic acid derivative that
accounts for 85% of clopidogrel related circulating com-
pounds. The CYP450 mediated steps, whose good function
is crucial for the adequate pharmacodynamic process,
compete with the esterase pathway. Several CYP450 enzyme
isoforms with different contributions are responsible for
the oxidation of the thiophene ring of clopidogrel to
2-oxoclopidogrel (first oxidation step: CYP1A2, 35.8%;
CYP2B6, 19.4%; and CYP2C19, 44.9%), which is further
oxidised (second oxidation step: CYP2B6, 32.9%; CYP2C9,
6.76%; CYP2C19, 20.6%; and CYP3A4, 39.8%), resulting
in the opening of the thiophene ring and the formation of
both a carboxyl and a thiol group [45,47]. The latter forms
a disulfide bridge with the two extracellular cysteine
residues located on the ADP P2Y12 receptor expressed on
the platelet surface and causes an irreversible blockade of
ADP binding for the platelet’s life span [48]. Among the
different CYP450 isoenzymes involved in clopidogrel
metabolism, CYP2C19 contributes substantially to both
oxidative steps of the clopidogrel conversion to its active
metabolite explaining the pivotal role of genetic poly-
morphisms in the gene coding these enzyme isoforms.
In particular, a single nucleotide polymorphism (SNP)
(CYP2C19*2) has been associated with inactivation of
the enzyme and impaired metabolism of drugs, including
clopidogrel, via this pathway.
Article highlights.
. MACEs and in particular ST, a potentially lethal
complication, are a critical clinical problem in the
management of patients undergoing percutaneous
coronary revascularisation with stent implantation. Dual
antiplatelet treatment with aspirin and clopidogrel is
mandatory in patients undergoing stent implantation.
High on-treatment platelet reactivity has been associated
with increased risk of thrombotic complications.
. The prodrug clopidogrel needs conversion to its active
metabolite by hepatic CYP enzyme system. CYP2C19 is
one of the most relevant CYP450 isoforms involved in the
drug metabolism.
. Inadequate drug compliance, drug–drug interactions,
age, diabetes mellitus, elevated body mass index and left
ventricle ejection function, inflammation and accelerated
platelet turnover are determinants of high on-clopidogrel
platelet reactivity.
. CYP2C19*2 polymorphism is associated with decreased
metabolisation of clopidogrel and poor antiplatelet effect
both in healthy subjects and high risk vascular patients on
dual antiplatelet therapy.
. CYP2C19*2 polymorphism is associated with increased
adverse cardiovascular events and in particular the severe
complication of ST.
. Future prospective studies, taking into account
CYP2C19*2 genotypes, residual platelet reactivity,
drug–drug interaction, as well as traditional and
procedural risk factors, are needed for the identification of
the therapeutic strategy that provides the best benefit for
the single subject.
This box summarises key points contained in the article.
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3. Non-pharmacogenetic mechanisms of high
on-clopidogrel platelet reactivity
In this section, some of the numerous potential or well-
documented non-pharmacogenetic mechanisms that could
contribute to high on-clopidogrel platelet reactivity are
reported (Figure 1). All these mechanisms could interact
with the CYP2C19*2 polymorphism in determining the
risk of occurrence of MACE, including ST, in high risk
vascular patients.
3.1 Compliance
Clopidogrel non-compliance may represent a critical issue as
cessation of clopidogrel therapy was observed in ~ 15%
(within 30 days) of patients with coronary artery disease
(CAD) [49] and in 18.4% (at 3 months) and £ 38.4%
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Figure 1. Mechanisms of clopidogrel response variability.
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Figure 2. Mechanism of action of clopidogrel.
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(at 1 year) in a cohort of patients after stroke [50], and it was a
well-known risk factor for ST [51]. With regard to compliance,
it is critical to separate the evidence into acute (in-hospital)
and chronic (outpatient) long-term setting.
3.2 Clopidogrel–proton pump inhibitor interaction
A growing body of evidences has recently been accumulated
about the interaction between the proton pump inhibitors
(PPIs) and clopidogrel in influencing platelet reactiv-
ity [22,52,53]. It is estimated that ~ 15% of an absorbed
clopidogrel dose is converted to an active thiol metabolite,
mainly by the hepatic CYP450 isoenzymes [46]. One of these
isoenzymes, the CYP2C19 isoform, is involved in the meta-
bolism of many of the PPIs, which are also inhibitors of the
CYP2C19 isoenzyme in varying degrees [54]. The capability of
PPIs to inhibit CYP2C19 activity would reduce the active
metabolite of clopidogrel generation and cause a diminished
platelet response to clopidogrel. In addition to this mecha-
nism, PPIs may influence the antiplatelet clopidogrel response
through the variability of intestinal absorption of clopido-
grel [55,56]. PPIs are substrates and inhibitors of the intestinal
efflux transporter P-glycoprotein, a key factor for intestinal
absorption of clopidogrel [54]. Alterations in P-glycoprotein
activity could potentially affect plasma concentrations of
clopidogrel and hence the concentration of active metabolite.
Gilard and coworkers documented for the first time that the
contemporary administration of clopidogrel and omeprazol
was associated with a reduced platelet inhibition related
to P2Y12 receptor in 105 CAD patients [57]. In the
OCLA (Omeprazole CLopidogrel Aspirin study) trial [52]
140 CAD patients undergoing stent implantation on dual
antiplatelet treatment were randomised to receive omeprazole
20 g/day or placebo for 7 days. This treatment significantly
decreased the effect of clopidogrel on platelet reactivity as
tested by platelet vasodilator-stimulated phosphoprotein
(VASP) phosphorylation assay [52]. The influence of panto-
prazole and esomeprazole on the clopidogrel antiplatelet
response was assessed in two different studies that evaluated
300 and 100 patients undergoing PCI, respectively [22,53]. In
these ex vivo studies, the intake of pantoprazole or esome-
prazole was not able to impair the platelet inhibition by
clopidogrel. A recent ex vivo study has evaluated the effect
of pantoprazole and omeprazole on inhibition by clopidogrel
in 104 non-ST-segment elevation (NSTE) ACS patients and
found, after 1 month of treatment, a significantly reduced
platelet inhibition by omeprazole but not by pantoprazole [58].
Contrasting data about the capability of PPI administration
to influence the risk of clinical events are available. In
13,636 patients with acute myocardial infarction (AMI)
treated with clopidogrel, the use of PPIs was associated
with an increased risk of AMI [20]. However, the use of
pantoprazole did not significantly affect the risk of AMI,
whereas the other PPIs were associated with an increased
risk of ~ 40%. In the retrospective study of 8,205 patients
with ACS, the use of clopidogrel plus PPIs (at discharge,
during follow-up or both) was associated with an increased
risk of death or rehospitalisation for ACS compared with the
use of clopidogrel without PPIs. By analysing the different
PPIs in relation to adverse outcomes, the earlier mentioned
study failed to demonstrate a significant difference between
omeprazole and raboprazole [23]. Recently, the authors of the
PRINCIPLE-TIMI (Prasugrel in comparison to Clopidogrel
for inhibition of Platelet Activation and Aggregation-
Thrombolysis in Myocardial Infarction) 44 and the
TRITON-TIMI (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition-Thrombolysis
in Myocardial Infarction) 38 trials retrospectively analysed
data in order to verify the possible interactions between the
use of PPIs, platelet function and adverse cardiovascular events
in relation to both clopidogrel and prasugrel. In both trials, the
use of PPIs was not significantly associated with an increased
risk of ischemic events in patients treated with clopidogrel
and with prasugrel and it was confirmed at the subgroup
analysis with the single PPI (omeprazole, pantoprazole,
esomeprazole and lansoprazole) in both sets of patients [21].
3.3 Age
The available evidence demonstrates that advanced age is
associated with a significantly high percentage of patients
with high on-clopidogrel platelet reactivity. One of the
possible causes is related to the fact that the conversion of
clopidogrel to its active metabolite may be impaired in older
patients [59,60]. Recently, in a prospective study [61] that
evaluated 191 patients who underwent PCI, ADP-inducible
platelet reactivity increased linearly with age after adjustment
for cardiovascular risk factors, type of intervention, medica-
tion, C-reactive protein and renal function. At variance, the
study by Price and coworkers [62] evaluating various factors
that may affect ADP-inducible platelet reactivity in patients
on continuous clopidogrel therapy demonstrated no effect of
age ‡ 75 years on ADP-inducible platelet reactivity [62]. This
discrepancy may be attributable to the duration of clopidogrel
therapy. Most of patients in the study by Gremmel et al.
received a loading dose of clopidogrel prior to angioplasty,
while the Price study assessed platelet aggregation mainly in
patients on continuous clopidogrel therapy [61,62]. Therefore,
the attenuation of clopidogrel-mediated platelet inhibition at
an advanced age may be a phenomenon of the initial phase of
antiplatelet therapy.
3.4 Diabetes mellitus
Diabetes mellitus is a clinical condition characterised by
enhanced platelet reactivity that exposes diabetic patients to
an increased risk of atherothrombotic events. In fact, platelets
in diabetics respond more frequently even to subthreshold
stimuli, are consumed more rapidly and thus contribute to
accelerated thrombopoiesis compared to platelets in non-
diabetic individuals [63]. It has been documented that high
on-clopidogrel platelet reactivity is more prevalent in diabetic
than in non-diabetic patients [64-66]. In particular, type 2
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
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diabetic patients undergoing elective PCI have approximately
a fourfold increase in the number of non-responders at 24 h
following a standard 300 mg loading dose: moreover, platelet
reactivity is persistently elevated in diabetic patients even in
the maintenance phase of clopidogrel and is highest among
those requiring insulin therapy [64].
3.5 Inflammation
Recent studies have documented a significant and indepen-
dent association between platelet hyper-reactivity and both
routinary inflammatory markers (such as erythrocyte sedi-
mentation rate and leukocyte number) [67] and unbalanced
pro-inflammatory/anti-inflammatory cytokine levels [24]. In
ACS patients on dual antiplatelet treatment, during the acute
phase of the disease, pro-inflammatory cytokine levels not
sufficiently compensated by anti-inflammatory cytokines are
able to modulate platelet hyper-reactivity [24]. Interestingly,
Antonino and coworkers demonstrated that patients treated
with long-term clopidogrel and aspirin therapy who under-
went elective PCI had less inflammation, indicated by specific
biomarkers (C reactive protein and other proinflammatory
cytokines), compared with clopidogrel-naive patients, suggest-
ing that long-term clopidogrel therapy is associated with an
anti-inflammatory effect [68].
3.6 Platelet turnover and reticulated platelets
An elevated turnover of the circulating platelet pool yields a
larger population of young platelets that are more reactive
than an older population of platelets. The younger platelets
had increased mean volume and a greater number of dense
granules than older circulating ones [69]. In both healthy
subjects and in patients with stable CAD, it has been dem-
onstrated that an increased platelet turnover, as reported by
the proportion of circulating RPs, exhibit significantly
increased aggregation and activation responses even after
dual antiplatelet therapy [26,69-71]. Moreover, in 372 ACS
patients on dual antiplatelet therapy the number of patients
with suboptimal or ‘low response’ to aspirin or clopidogrel or
both was clustered among patients with a high proportion of
circulating RPs [25].
3.7 von Willebrand factor and ADAMTS-13
The adhesion and activation of platelet at sites of vascular
injury is mediated by von Willebrand factor (VWF). VWF,
which is released from storage sites or secreted by endothelial
cells as ultra-large VWF (ULVWF), is rapidly cleaved through
intravascular proteolysis by ADAMTS-13 [72]. In the acute
phase of CAD and after the vascular injury induced by a
PCI, endothelial cells are activated and high amounts of
ULVWF are released [73]. ULVWF forms are able to binds
the glycoprotein 1b–IX complex and aggregate platelets [74]. In
physiological conditions the large multimeric forms are
rapidly cleaved by the ADAMTS-13 on the surface of
the endothelium, resulting in the generation of the normal
multimeric pattern of VWF [72,75]. When ADAMTS-13
activity is reduced, the ULVWFs accumulate and can induce
platelet aggregation [72]. High on-clopidogrel platelet reacti-
vity is associated with lower ADAMTS-13 activity accompa-
nied by elevated VWF levels [29], suggesting a modulatory
effect of the interplay between ADAMTS-13 and VWF on the
response to antiplatelet therapy in patients with a marked
endothelial activation, such as those with ACS who have
undergone PCI.
3.8 Red blood cells and leukocytes
Red blood cells and leukocytes are significantly implicated into
the pathogenesis of arterial thrombosis. Platelet–leukocyte
interactions play an important role in both adhesion and
activation of platelets, but red blood cells are also involved
in the interactions between platelets and vessel wall. In patients
with ACS the inhibition of platelets induced by aspirin is
modulated not only by the direct action on platelets, but
also by the erythrocyte deformability and the white blood
cell count [27] suggesting that all blood components, including
red blood cells, should be taken into account. Some hemor-
heologic variables are also associated with high on-treatment
platelet reactivity in patients with ACS on dual antiplatelet
therapy. In particular, decreased erythrocyte deformability is
significantly associated with increased platelet aggregation
induced by ADP [28]. A possible explanation for this association
is that erythrocytes with decreased deformability tend to release
a larger amount of ADP in the circulation compared to those
without [76] and ADP released can compete against clopidogrel
for purinergic receptors present on the platelet surface.
4. Association of CYP2C19 loss-of-function
polymorphism with high on-clopidogrel
platelet reactivity
Several polymorphisms in different genes coding isoforms of
CYP450 have been investigated as possible determinants of
the high on-clopidogrel platelet reactivity (genetic variants in
CYP3A4, CYP3A5, CYP1A2, CYP2B6, CYP2C9, CYP2C19,
ABCB1 genes). For the majority of the investigated poly-
morphisms results are negative or inconsistent. On the con-
trary, consistent data are available concerning a polymorphism
in one isoform of the CYP450, the CYP2C19. The
CYP2C19*2 loss-of-function polymorphism is a G681A
nucleotide substitution that introduces a splicing defect result-
ing in a truncated, non-functional protein, responsible for the
poor metaboliser phenotype [77].
4.1 Studies in healthy subjects
In 2006, Hulot and coworkers [34] demonstrated for the
first time that the CYP2C19 loss-of-function allele is associ-
ated with a marked decrease in platelet responsiveness to
clopidogrel in 28 young healthy male volunteers treated for
7 days with clopidogrel 75mg/day (Table 1). Fontana and
coworkers [78] replicated the CYP2C19*2 allele influence on
Giusti, Gori, Marcucci & Abbate
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clopidogrel responsiveness in 94 healthy subjects by assessing
the ADP-induced platelet aggregation after the 1-week course
of clopidogrel (300 mg on day 1, then 75 mg/day) and
showed that the CYP2C19*2 polymorphism explained
10% of the variability of clopidogrel responsiveness also
when the analysis was adjusted for age, platelet count, hemato-
crit, collagen lag time and fibrinogen and von Willebrand
levels. To determine the relationship between genetic variation
in CYP450 isoenzymes and the pharmacokinetic/pharmaco-
dynamic response to prasugrel and clopidogrel, Brandt and
coworkers [35] genotyped healthy subjects participating in
studies evaluating pharmacokinetic and pharmacodynamic
response to prasugrel (60 mg, n = 71) or clopidogrel
(300 mg, n = 74) for CYP1A2, CYP2B6, CYP2C19,
CYP2C9, CYP3A4 and CYP3A5 genetic variants. In subjects
receiving clopidogrel, the presence of the CYP2C19*2 loss-of-
function variant was significantly associated with lower expo-
sure to clopidogrel active metabolite, lower inhibition of
platelet aggregation at 4 h and poor-responder status. Simi-
larly, CYP2C9 loss-of-function variants, polymorphisms in
another gene coding a different CYP450 isoenzyme, were
significantly associated with lower exposure to clopidogrel
active metabolite, lower inhibition of platelet aggregation at
4 h and poor-responder status. For prasugrel, there was no
relationship observed between CYP2C19 or CYP2C9 loss-of-
function polymorphisms and exposure to the active metabolite
of prasugrel or pharmacodynamic response.
Recently, Mega and coworkers [39] have also confirmed that
in 162 healthy subjects on a 300-mg dose of clopidogrel,
carriers of at least one CYP2C19 reduced-function allele
(~ 30% of the study population) had a relative reduction
of 32.4% in plasma exposure to the active metabolite of
clopidogrel, as compared with noncarriers. Carriers also
had an absolute reduction in maximal platelet aggregation
in response to clopidogrel that was nine percentage points less
than that seen in noncarriers.
A total of 24 Korean subjects were divided into three groups
on the basis of their CYP2C19 genotype by Kim and co-
workers [79]: homozygous extensive metabolisers (homoEMs,
n = 8), heterozygous EMs (heteroEMs, n = 8) and poor
metabolisers (PMs, n = 8). After a single 300-mg loading dose
of clopidogrel on day 1, followed by a 75-mg/day mainte-
nance dose from days 2 to 7, they measured the plasma
levels of clopidogrel and assessed its antiplatelet effect as
inhibitory effect on ADP-induced platelet aggregation accord-
ing to the CYP2C19 genotype. The mean clopidogrel AUC
for PMs was 1.8- and 2.9-fold higher than that for heteroEMs
and homoEMs, respectively, and their Cmax values were
1.8- and 4.7-fold higher than that of heteroEMs and homo-
EMs, respectively. PMs also exhibited a significantly lower
antiplatelet effect than heteroEMs or homoEMs.
Umemura and coworkers [80], in 47 healthy Japanese
subjects, determined plasma concentrations of the active
metabolite before and at 0.25, 0.5, 1, 2, 4 and 8 h after
treatment with clopidogrel 300 mg. Moreover, before and at
1, 4, 6 and 24 h after the treatment, they measured inhibition
of platelet aggregation to ADP and VASP. They confirmed
that the *2 allele is a determinant for the formation of the
active metabolite and demonstrated that the pharmacokinetic
parameters, AUC and Cmax of the active metabolite were well
Table 1. Association of CYP2C19*2 loss-of-function polymorphismwith response variability to clopidogrel treatment in
healthy subjects.
Study No. of
subjects
Treatment Functional evaluation CYP2C19*2
carriers (%)
Association
Hulot et al. [34] 28 Caucasian males 75mg/day for 7 days 10 µM ADP-induced PA 28.6 Yes
Fontana et al. [78] 94 Caucasians 300 mg the first day,
then 75 mg/day
for 7 days
20 µM ADP induced PA 27.7 Yes
Brandt et al. [35] 74 Caucasians
(57 males/
17 females)
300 mg 20 µM ADP-induced PA
Active metabolite by
LC + MS
25.8 Yes
Kim et al. [79] 24 Koreans 300 mg the first day,
then 75 mg/day
for 7 days
5 µM ADP-induced PA
PCC by LC + MS
66.6
(selected)
Yes
Umemura et al. [80] 47 Japanese 300 mg 20 µM ADP-induced PA
VASPph
Active metabolite by
LC + MS
61.7 Yes
Mega et al. [39] 162 (130 males/
32 females)
300 – 600 mg ±
75 mg/day for 7 days
20 µM ADP-induced PA
Active metabolite by
LC + MS
34.0 Yes
LC + MS: Liquid chromatography with tandem mass spectrometry; PA: Platelet aggregation; PCC: Plasma concentrations of clopidogrel;
VASPph: Vasodilator-stimulated phosphoprotein phosphorylation state of whole blood for which we performed a dual colour flow cytometric assay.
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correlated with platelet reactivity index by VASP and inhibi-
tion of platelet aggregation to ADP. Their findings suggest
that low or no responsiveness to clopidogrel is mainly caused
by the lower metabolic formation of the metabolite, but not
because of the poor sensitivity of the platelet P2Y12 receptor.
They also observed that CYP2C19 polymorphism showed a
marked interethnic difference in the incidence of carriers of
CYP2C19*2 polymorphism. The prevalence of carriers is
much greater (18 – 23%) in Asian people than that
(~ 3%) in Caucasian populations [81]. In a meta-analysis [82],
21% of patients treated with clopidogrel achieved low or no
ex vivo inhibition of ADP-induced platelet aggregation in
American or European populations. Based on the results in
this study, it is estimated that > 30% of Asian patients show
less responsiveness to clopidogrel.
Recently, in the Pharmacogenomics of Antiplatelet Inter-
vention Study, Shuldiner and coworkers [83] administered
clopidogrel 300 mg p.o. as a loading dose followed by
75 mg/day for 7 days to 429 healthy Amish persons and
measured response by ex vivo platelet aggregometry (baseline
platelet aggregation and at 1 h following the last dose of
clopidogrel). In this population, a genome-wide association
study was performed followed by genotyping the loss-of-
function CYP2C19*2 variant. They observed that platelet
response to clopidogrel was highly heritable (h2 = 0.73;
p < 0.001). A total of 13 SNPs on chromosome 10q24
within the CYP2C18–CYP2C19–CYP2C9–CYP2C8 cluster
were associated with diminished clopidogrel response. These
SNPs were in strong linkage disequilibrium with each other
with rs12777823 being the most significantly associated SNP
(p = 1.5  10-13 for the additive model). The rs12777823
polymorphism was in strong linkage disequilibrium with the
CYP2C19*2 variant, and was associated with diminished
clopidogrel response, accounting for 12% of the variation
in platelet aggregation to ADP (p = 4.3  10-11). No other
genomic region revealed association signals that displayed
exceess genome-wide significance (p < 1.0  10-7). These
data suggested that in this population of healthy subjects
the common loss-of-function CYP2C19*2 variant could
account for most of the association signal detected in the
genome-wide association study.
4.2 Studies in high risk vascular patients
In 2007, Giusti and coworkers [36] studied two polymor-
phisms affecting clopidogrel metabolism (one in the +12
position of intron 10 of the CYP3A4 gene and one a
G681A substitution determining a splicing alteration of the
CYP2C19 gene) and one polymorphism of the P2Y12
ADP platelet receptor (T744C marker of the H1/H2 haplo-
type) (Table 2). The role of these three polymorphisms in
modulating platelet function in ACS patients on dual anti-
platelet treatment who has undergone PCI was evaluated.
Three polymorphisms were found to be important in inter-
fering with the mechanism of action of clopidogrel: the
polymorphisms of the two isoforms of the CYP450, by
interfering with the formation of the active metabolite that
binds irreversibly to the platelet ADP receptor P2Y12, and the
polymorphism of the receptor by interfering with its function.
In that paper, for the first time, it was reported that in
1,419 high risk vascular patients on dual antiplatelet treatment
the *2 allele of the CYP2C19 gene was associated with higher
platelet aggregability and residual platelet reactivity. Carriers
of the *2 allele of the polymorphism had significantly higher
platelet aggregation values than noncarriers of the *2 allele
after 2 and 10 µM ADP, and after arachidonic acid (AA)
stimuli. In particular, homozygous subjects for the *2 allele
had significantly higher platelet aggregation after ADP stimuli
than heterozygous carriers. No differences in platelet aggre-
gation values were observed after the three different stimuli in
the overall studied population according to the other two
polymorphisms investigated (P2Y12 T744C and CYP3A4
IVS10 + 12G/A). The genotype distribution of CYP2C19
polymorphism significantly differed between patients with
and without residual platelet reactivity (RPR) evaluated by
10 µM ADP induced platelet aggregation. The prevalence of
carriers of the *2 allele was higher in patients with ADP-RPR
than in those without. Similar results were also observed in
patients with AA-RPR as compared to those without. In the
multivariate linear regression model with ADP 2 or 10 µM
or log(AA) platelet aggregation as dependent variable and
age, gender, hypertension, diabetes mellitus, dyslipidemia
and smoking habit as independent variables, age, diabetes
and CYP2C19*2 polymorphisms remained significant and
independent risk factors for antiplatelet treatment variability.
Several other groups confirmed that the *2 allele of
the CYP2C19 gene is associated with higher platelet aggreg-
ability and residual platelet reactivity in similar and different
clinical settings.
Frere and coworkers [84] in 603 patients with non-ST
elevation ACS demonstrated that the CYP2C19*2 allele
influences post-treatment platelet reactivity and clopidogrel
response assessed by ADP induced platelet aggregation, VASP
phosphorylation index and ADP induced P-selectin expres-
sion. They also demonstrated no effect of CYP3A4*1B and
CYP3A5*3 [84].
Trenk and coworkers [37] studied and followed-up
797 patients undergoing elective coronary stent implantation;
they showed an association between CYP2C19*2 polymor-
phism and high (> 14%) ADP residual platelet aggregation on
clopidogrel treatment.
In 237 symptomatic CAD patients (both stable angina or
ACS patients), Geisler and coworkers [85] observed that
CYP2C19*2 carriers showed significantly increased residual
platelet aggregation compared with noncarriers.
In 60 patients undergoing elective PCI in the randomised
PRINC (Plavix Response in Coronary Intervention) trial,
Gladding and coworkers [86] measured platelet function using
the VerifyNow P2Y12 analyser after a loading dose of 600 or
split 1,200 mg and a maintenance dose of 75 or 150 mg/day.
CYP2C19*1*1 carriers had greater platelet inhibition 2 h after
Giusti, Gori, Marcucci & Abbate
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a 600-mg dose, compared with platelet inhibition in
CYP2C19*2 or *4 carriers and CYP2C19*17 carriers.
CYP2C19*2 or *4 carriers had greater platelet inhibition
with the higher loading dose than with the lower dose
at 4 h and responded better with the higher maintenance
dose regimen.
The association of the CYP2C19*2 polymorphism with a
residual platelet reactivity was also observed in Japanese
patients by Jinnai and coworkers [87], in whom a higher
prevalence of the carriers of the *2 allele was found (56%)
with respect to their Western counterparts (~ 30%). On the
other hand, the same authors had previously reported that the
effectiveness of clopidogrel in the Japanese is weaker than that
in Western people [88], but the ratios of CYP2C19 poor
metabolisers in the Western population are less (~ 1 – 7%)
when compared to that in Asians (~ 12 – 23%) [89].
5. Association of CYP2C19 loss-of-function
polymorphism with the occurrence of major
adverse cardiovascular events
Recently, different groups contemporarily demonstrated in
different clinical settings and at different follow-up times that
CYP2C19*2 is a determinant of the occurrence of MACE and
in particular of ST (Table 3) [38-42]. Only one paper failed to
demonstrate the role of the CYP2C19*2 loss-of-function
polymorphism in the occurrence of MACE or ST. In fact,
the paper by Trenk and coworkers [37] did not demonstrate a
relationship between genotype and increased occurrence of
adverse 1-year clinical outcome (death from any cause and
myocardial infarction) of elective PCI with drug-eluting or
bare-metal stents (Table 3). They showed an association
between CYP2C19*2 polymorphism and platelet function
phenotype (see previous paragraph) as well as an association
of high-on clopidogrel platelet reactivity with poor clinical
outcome. On the other hand, in their patient population they
had only 280 patients out of 797 with at least one DES. In the
group of patients with at least one DES, the percentage of
patients with an event was 3.3% (3 of 90) among carriers
of the *2 allele versus 2.1% (4 of 190) among wild-type
homozygotes (p = 0.684).
Simon and coworkers [38], in 2,208 patients with an AMI
and on clopidogrel therapy, assessed the relation of allelic
variants of genes modulating clopidogrel absorption [ATP-
binding cassette, subfamily B (MDR/TAP), member 1
(ABCB1)], metabolic activation (CYP3A5 and CYP2C19)
and biologic activity [purinergic receptor P2Y, G-protein
coupled, 12 (P2RY12) and integrin, beta 3 (ITGB3)] to the
risk of death from any cause, non-fatal stroke or myocardial
infarction during 1 year of follow-up.
None of the selected polymorphisms in CYP3A5, P2RY12
or ITGB3 were associated with a risk of an adverse outcome.
Patients with two variant alleles of ABCB1 (TT genotype) had
a higher rate of cardiovascular events at 1 year than those with
the ABCB1 wild-type genotype (CC) [15.5 versus 10.7%;
adjusted hazard ratio (HR), 1.72; 95% confidence interval
(CI), 1.20 – 2.47]. Moreover, they demonstrated that patients
carrying CYP2C19 loss-of-function alleles (*2, *3, *4 or *5)
Table 2. Association of CYP2C19*2 loss-of-function polymorphismwith response variability to clopidogrel treatment in
high risk vascular patients.
Study No. of subjects Treatment Functional evaluation CYP2C19*2
carriers (%)
Association
Giusti et al. [36] 1,419 PCI + stent 600 mg LD +
75 mg/day
maintaining
10 µM ADP-induced PA 31.4 Yes
Frere et al. [84] 603 NSTE 600 mg LD 10 µM ADP-induced PA
VASPph
ADP-induced P-selectin
27.6 Yes
Trenk et al. [37] 797 PCI + stent 600 mg LD +
75 mg/day
maintaining
5 and 20 µM ADP-induced PA
ADP-induced P-selectin,
activated GPIIa/IIIb, CD63,
CD40 L, CD41 (GPIIb)
30.7 Yes
Geisler et al. [85] 237 PCI 600 mg LD +
75 mg/day
maintaining
20 µM ADP-induced PA 26.0 Yes
Gladding et al. [86] 60 PCI 600/1,200 mg LD +
75/150 mg/day
VerifyNow P2Y12 Yes
Jinnai et al. [87] 30 PCI (Japanese) 300 mg LD +
75 mg/day
maintaining
5 µM ADP-induced PA 56.0 Yes
GPIIa/IIIb: Glycoprotein IIa/IIIb (PAC-1); GPIIb: Glycoprotein IIb; LD: Loading dose; NSTE: Non-ST elevation; PA: Platelet aggregation; PCI: Percutaneous coronary
intervention; VASPph: Vasodilator-stimulated phosphoprotein phosphorylation state of whole blood for which we performed a dual colour flow cytometric assay.
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
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had a higher rate of subsequent cardiovascular events during
1 year of follow-up (HR 1.98, 95%CI 1.10 – 3.58) that those
who were not. The presence of two variant alleles of
CYP2C19, but not ABCB1, was found to be associated
with an increase by a factor of 3.58 (95%CI 1.71 – 7.51)
in the rate of cardiovascular events among the 1,535 patients
who underwent PCI during hospitalisation as compared with
those who did not.
Mega and coworkers [39] tested the association between
functional genetic variants in CYP genes [CYP2C19, CYP,
family 2, subfamily C, polypeptide 9 (CYP2C9), CYP, family
2, subfamily B, polypeptide 6 (CYP2B6), CYP3A5, CYP,
family 3, subfamily A, polypeptide 4 (CYP3A4), and CYP,
family 1, subfamily A, polypeptide 2 (CYP1A2)], plasma
concentrations of active drug metabolite and platelet inhibi-
tion in response to clopidogrel in 162 healthy subjects
(see previous paragraph). Furthermore, they examined the
association between these genetic variants and cardiovas-
cular outcomes in a separate cohort of 1,477 subjects with
ACS who were treated with clopidogrel in the TRITON-
TIMI (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with
Prasugrel-Thrombolysis in Myocardial Infarction) 38 trial.
In the cohort of 1,477 ACS patients who were treated with
clopidogrel in the TRITON-TIMI 38 trial, they demon-
strated that carriers of the reduced-function CYP2C19*2
allele had significantly lower levels of the active metabolite
of clopidogrel, diminished platelet inhibition and a higher
rate of MACE at 15 months (death from cardiovascular
causes, myocardial infarction or stroke; HR 1.53, 95%CI
1.07 – 2.19) and an increase by a factor of 3 in the risk of ST
(HR 3.09, 95%CI 1.19 – 8.00).
In 259 young patients (< 45 years) who survived a first
myocardial infarction and were exposed to clopidogrel treat-
ment for ‡ 1 month, Collet and coworkers [40] assessed
whether the CYP2C19*2 polymorphism affected long-
term prognosis in those chronically treated with clopidogrel.
They chose as primary end-point a composite of cardiovas-
cular death, non-fatal myocardial infarction and urgent
revascularisation occurring during exposure to clopidogrel
and ST as secondary end-point. In this cohort of premature
myocardial infarction patients, the primary end-point
occurred more frequently in carriers than in noncarriers
[15 versus 11 events; HR 3.69 (95%CI 1.69 – 8.05),
p = 0.0005]. Similar results were obtained in relation to
the secondary end-point for which they observed an increase
in the risk of ST by a factor of 6 [8 versus 4 events; HR 6.02
(1.81 – 20.04), p = 0.0009]. After multivariable stepwise
Cox regression analysis considering in the model all the
baseline characteristics, especially those known to be asso-
ciated with recurrent acute coronary thrombosis and poor
response to clopidogrel (including body mass index, smoking
status, diabetes status, stent implantation, initial ST-segment
elevation myocardial infarction and use of PPIs) if they were
significant at a = 0.20 in the univariate model, the
CYP2C19*2 genetic variant was the only independent
Table 3. Association of CYP2C19*2 loss-of-function polymorphism with occurrence of MACEs or intra-ST alone.
Study No. of
subjects
Treatment Outcome
(follow-up)
CYP2C19
alleles
Association
Trenk et al. [37] 797 PCI + stent 600 mg LD +
75 mg/day
maintaining
Death + MI (1 year) *2 No
Simon et al. [38] 2,208 AMI
(1535 PCI)
300 mg mean LD +
75 mg/day
maintaining
Death + non-fatal stroke +
MI (1 year)
Any
two*2,*3,*4,*5
Yes (HR = 1.98)
Yes (HR = 3.58)
Mega et al. [39] 1,477 ACS 300 mg LD +
75 mg/day
maintaining
Cardiovascular death + MI +
stroke (15 months)
ST (15 months)
*2 Yes (HR = 1.53)
Yes (HR = 3.09)
Collet et al. [40] 259 MI
(< 45 years)
600 mg LD +
75 mg/day
maintaining
Death + MI + coronary
revascularisation
(6 months)
ST (6 months)
*2 Yes (HR = 3.69)
Yes (HR = 6.02)
Giusti et al. [41] 772 PCI + DES 600 mg LD +
75 mg/day
maintaining
Cardiovascular death +
ST (6 months)
ST (6 months)
*2 Yes (OR = 2.70)
Yes (OR = 3.43)
Sibbing et al. [42] 2,485 PCI +
stent
600 mg LD +
75 mg/day
maintaining
ST (30 days) *2 Yes (HR = 3.81)
ACS: Acute coronary syndrome; AMI: Acute myocardial infarction; DES: Drug-eluting stent; HR: Hazard ratio; LD: Loading dose; MACEs: Major adverse cardiovascular
events; MI: Myocardial infarction; OR: Odds ratio; PCI: Percutaneous coronary intervention; ST: Stent thrombosis.
Giusti, Gori, Marcucci & Abbate
Expert Opin. Drug Metab. Toxicol. (2010) 6(4) 9
Ex
pe
rt 
O
pi
n.
 D
ru
g 
M
et
ab
. T
ox
ic
ol
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
dr
 B
et
ti 
G
iu
sti
 
Fo
r p
er
so
na
l u
se
 o
nl
y.
predictor of cardiovascular events [HR 4.04 (1.81 – 9.02),
p = 0.0006].
In the framework of the Low Responsiveness to
Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent
Thrombosis (RECLOSE) trial, Giusti and coworkers [41]
evaluated the role of the CYP2C19*2 polymorphism in the
occurrence of drug-eluting ST (primary end-point) and the
composite feature of cardiac mortality and drug-eluting
ST (secondary end-point) in a 6-month follow-up of
772 patients undergoing PCI on dual-antiplatelet treatment.
Patients with ST or the composite of cardiac mortality and
ST showed a higher prevalence of carriers of the *2 allele (54.1
versus 31.3%; p = 0.025 and 51.7 versus 31.2%; p = 0.020,
respectively). In this clinical setting of high risk vascular
patients, the authors demonstrated that the CYP2C19*2
polymorphism was an independent risk factor for ST when
the effect of the polymorphism was evaluated in a model
adjusted for high on-clopidogrel platelet reactivity evaluated
by ADP induced platelet aggregation (ADP-RPR), traditional
cardiovascular risk factors and clinical and procedural risk
factors for ST (such as total chronic occlusion, multivessel
disease, bifurcation lesion, AMI, previous myocardial infarc-
tion, total stent length and left ventricular ejection fraction)
(OR 3.43, 95%CI 1.01 – 12.78). Moreover, subjects with the
contemporary presence of the CYP2C19*2 allele and ADP-
RPR showed a strong risk of ST or ST and cardiac mortality
(OR 5.79, 95%CI 1.04 – 39.01 and 11.45, 95%CI
1.84 – 71.27, respectively).
Sibbing and coworkers [42] assessed the impact of the
CYP2C19 loss-of-function polymorphism on ST following
PCI performed after pre-treatment with clopidogrel. The
primary end-point of the study was the incidence of definite
ST within 30 days following PCI. A total of 2,485 patients
with CAD undergoing PCI were enrolled in this study.
The cumulative 30-day incidence of ST was significantly
higher in CYP2C19*2 allele carriers (*1/*2 heterozygotes or
*2/*2 homozygotes) versus CYP2C19 wild-type homozygotes
(*1/*1) (1.5% in CYP2C19*2 allele carriers versus 0.4%
in CYP2C19 wild-type homozygotes, HR 3.81, 95%
CI1.45 – 10.02, p = 0.006, after adjustment for confounding
variables). The risk of ST was highest (2.1%) in patients with
the CYP2C19 *2/*2 genotype (p = 0.002).
Recently, Sofi and coworkers [90] performed a meta-analysis
on data available for a total of 7,950 patients from six cohort
prospective studies who were followed for a time ranging
from 6 months to 8.4 years [37-42] reinforcing the observation
that the CYP2C19*2 polymorphism is associated with the
increased risk of MACE and in particular ST. The summary
risk ratios for included cohort prospective studies showed a
significant association between the CYP2C19*2 polymor-
phism and an increased risk of MACE in the follow-up
[RR: 1.80 (1.02 – 3.19); p = 0.04]. When studies evaluating
ST (n = 4) for a total of 4,975 patients were considered, the
presence of the variant allele was associated with an increased
risk of ST [RR: 2.82 (1.43 – 5.56); p = 0.0001].
6. Expert opinion: towards personalised
medicine
Due to the large body of evidences accumulated, the issue of
whether, in subjects with ACS, the identification of
CYPC19*2 carriers is appropriate to improve the risk strat-
ification, the therapeutic management of patients and conse-
quently to reduce the occurrence of MACEs and in particular
ST could be raised.
Several strategies could be considered to solve the problem
of the high on-treatment platelet reactivity despite the dual
antiplatelet treatment in high risk vascular patients: a higher
dosage of clopidogrel, a different antiplatelet drug among
those at present under clinical evaluation (prasugrel, ticagrelor,
cangrelor) or the addition of a third antiplatelet drug such
as ilostal.
Bonello and coworkers [91] demonstrated that individually
tailored loading dose of clopidogrel to obtain a VASP index
< 50% after a first clopidogrel loading dose of 600 mg in
patients with high on-treatment platelet reactivity translated
into an improved outcome [91,92]. Recently, the same group
observed that high on-treatment platelet reactivity in homo-
zygotes for CYP2C19*2 loss-of-function polymorphism could
be overcome by dose adjustment according to platelet reac-
tivity monitoring [93]. Patients with a VASP < 50% after the
first clopidogrel loading dose were considered good respon-
ders. Patients with a VASP ‡ 50% despite the 600-mg loading
dose were considered to have high on-treatment platelet
reactivity. For these patients clopidogrel was adjusted indi-
vidually, before PCI, to obtain a VASP index < 50% using
up-to three additional loading dose of 600 mg each prescribed
at 24-h intervals. As regards new antiplatelet drugs, the
TRITON-TIMI 38 trial demonstrated that, compared with
clopidogrel, treatment with prasugrel resulted in a significantly
lower rate of ischemic events and more bleeding among
patients presenting with ACS with planned PCI [94]. Both
clopidogrel and prasugrel are prodrugs that require biotrans-
formation to active metabolites by CYP450 enzymes.
Although the active metabolites of both drugs have similar
affinity for the P2Y12 receptor in vitro, the in vivo differences
in response appear to be mediated predominantly by differ-
ences in the metabolic pathways leading to the formation of
the active metabolites [95]. Esterases shunt the majority of
clopidogrel to a dead-end inactive pathway, with the remain-
ing prodrug requiring two separate CYP-dependent oxidative
steps [47]. In contrast, esterases are part of the activation
pathway with prasugrel, and prasugrel is oxidised to its active
metabolite in a single CYP-dependent step, without an appar-
ent dead-end inactive pathway [96]. Among 238 healthy sub-
jects, Mega and coworkers [97] did not observe significant
attenuation of the pharmacokinetic or the pharmacodynamic
response to prasugrel in carriers versus noncarriers of at
least one reduced function allele for any of the CYP gene
tested (CYP2C19, CYP2C9, CYP2B6, CYP3A5, CYP1A2).
Consistent with these findings, in 1,466 patients with ACS
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
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treated with prasugrel no significant associations were found
between any of the tested CYP genotypes and risk of cardio-
vascular death, myocardial infarction or stroke [97]. On the
other hand, to the best of our knowledge, we cannot exclude
the fact that other polymorphisms, different from those
involved in clopidogrel pharmacogenetics, in genes coding
for different CYP450 isoforms or proteins involved in the
functional pathway of new antiplatelet agents might determine
a variability in their activity and therapeutic efficacy.
Several important issues should be considered in evaluating
the possibility of a tailored therapy that takes in account the
knowledge of CYP2C19*2 genotype. First of all the result of
the genotyping test would be available at the time of starting
clopidogrel and during the early high risk phase of the ACS
together with the evaluation of the phenotype, such as ADP-
induced platelet aggregation [14,15,98,99], VerifyNow Sys-
tem [16,17], the more specific flow cytometric assay of
P2Y12-mediated effect on phosphorylation of VASP in
PGE1-treated platelet [92,99] or a more global approach,
such as Multiplate whole blood aggregometry [100]. The
functional evaluation of the high on-clopidogrel platelet
reactivity has the potential benefit of identifying those who
are homozygous for the wild-type CYP2C19*1 allele but still
have a poor pharmacodynamic response to clopidogrel. In
fact, the findings by Giusti and coworkers [41], indicating that
the presence of ADP-RPR and the CYP2C19*2 polymor-
phism was the strongest predictor of ST complication or the
composite of ST and cardiac mortality with respect to the
CYP2C19*2 polymorphism and ADP-RPR per se, provide
the two insights that i) mining of the CYP2C19*2 polymor-
phism as a risk factor for ST is only partially linked to its role
in determining the ADP-RPR phenotype observed in the
acute periprocedural phase; and that ii) other genetic and
acquired determinants of RPR in addition to the CYP2C19*2
polymorphism might have a role in determining the clinical
outcome in these high risk vascular patients.
Several new drugs (prasugrel, ticagrelor, cangrelor) that
target P2Y12 are being developed and will be available
soon. These drugs achieve consistently high levels of receptor
inhibition, and potentially provide solutions to the problem of
variability in the response to clopidogrel. Nevertheless, the
possibility of a higher incidence of bleeding or other drug–
drug interaction or possible nonresponsiveness due to other
genetic or acquired factors needs to be further explored for
these new drugs.
In conclusion, a large body of evidence exists demonstrating
that the CYP2C19*2 genetic variant is a major determinant of
prognosis in high risk vascular patients who have undergone
PCI and have received clopidogrel treatment. Available data
underline the urgent need of prospective studies aimed at
clarifying whether a more intense clopidogrel therapy or the
use of a different drug (e.g., prasugrel) designed for correction
of inadequate suppression of platelet reactivity could improve
the outcome, incidence of MACE and in particular of ST, in
high risk vascular patients without increasing the major bleed-
ing complications. These studies, besides the traditional car-
diovascular risk factors, and the clinical and procedural risk
factors for MACE and ST, should take into account the genetic
profile as well as the residual platelet reactivity phenotype and
the possible drug interactions (especially with drugs metabolised
by the same CYP450 isoforms) to identify the better pharma-
cological strategy to apply for the more efficacious management
and safety of these high risk vascular patients.
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